Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

5.17
-0.2400-4.44%
Volume:14.23K
Turnover:75.50K
Market Cap:3.52M
PE:-0.12
High:5.57
Open:5.50
Low:5.15
Close:5.41
52wk High:24.90
52wk Low:5.09
Shares:681.56K
Float Shares:459.20K
Volume Ratio:1.20
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-42.3158
EPS(LYR):-80.3223
ROE:-231.27%
ROA:-110.91%
PB:0.63
PE(LYR):-0.06

Loading ...

Mar 30, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Mar 28, 2023

Major Issues Report

8-K - Current report
Mar 28, 2023

[Rev.]Annual Report

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 20, 2023

Major Issues Report

8-K - Current report
Mar 16, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 16, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 16, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Mar 15, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Mar 14, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 14, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 13, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 13, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 13, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Mar 13, 2023

Major Issues Report

8-K - Current report
Mar 01, 2023

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Feb 21, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 21, 2023

Major Issues Report

8-K - Current report
Feb 08, 2023

Major Issues Report

8-K - Current report
Jan 18, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Dec 15, 2022

Major Issues Report

8-K - Current report